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Cardiovascular disease (CVD) claims ~20 million lives worldwide 
annually, accounting for a third of global deaths. More than 75% of 
deaths from CVD occur in low- and middle-income countries 
(LMICs). Eighty-five percent of all CVD deaths worldwide are due 
to myocardial infarction (MI) and stroke.[1] In sub-Saharan Africa 
(SSA), heart failure is the dominant form of CVD; the causes are 
largely non-ischaemic, i.e. hypertension, cardiomyopathy, rheumatic 
heart disease, pericardial disease and cor pulmonale.[2] The high 
prevalence and changing profile of CVD in SSA are directly linked 
to population dynamics and epidemiological transition in some 
of the most vulnerable societies. The epidemiological transition, 
characterised by an increase in obesity, hypertension and diabetes 
mellitus, has seen an increase in non-communicable diseases (NCDs) 
in urban, semi-urban and rural areas. The burden of NCDs is likely 
to increase further, as antiretroviral therapy reduces mortality and 
affects the cardiovascular system. Further, infections and NCDs are fuelled 
by common precursors such as poverty and poor education.[3] CVD 
related to genetic predisposition is gaining increased awareness 
in SSA owing to advances in genetic technologies, resulting in 
substantial expansion of knowledge of the genetic basis and 
mechanisms of CVD.[4] 
Table 1 provides a glossary of the genetic terminology used in this 
article.[5]
What are genetic variations?
Each human being is unique, but genetically, we are 99.9% the same. 
The remaining 0.1% is responsible for all the differences that make 
each one of us individual and is caused by genetic variation (GV). 
GV is the difference in DNA sequences between individuals within 
a population and can be caused by repair errors in the replication 
machinery. Variation occurs in germ cells and somatic cells. Only 
variation that arises in germ cells can be inherited from one 
individual by another and affect population dynamics, and ultimately 
evolution. Large changes to our genome may have no effect at all, 
whereas the change of a single nucleotide can have a huge impact. 
Mutations and recombination are major sources of variation.
There are three types of GV: (i) single-nucleotide polymorphisms 
(SNPs) are the most common, occurring about once every 1 000 bases; 
(ii) insertion or deletion of a single stretch of DNA sequence that can 
range from two to hundreds of base-pairs in length; and (iii) gene-
tic rearrangements that can affect several genes or large areas of a 
chromosome at once. GV includes both copy number variation and 
chromosomal rearrangement events.
Most variation is meaningless and does not affect our ability 
to survive or adapt. For example: (i) ‘silent mutations’ in DNA, 
which change the DNA, but not the amino acid sequence; (ii) other 
mutations may change the amino acid sequence of a protein, but not 
the overall function of that protein; and (iii) other polymorphisms 
do not seem to affect our survival at all. Other variations are positive 
and improve our ability to survive or adapt, e.g. mutations that cause 
sickle cell anaemia have a protective effect against malaria. Some 
variation leads to disease such as monogenic single-gene disorders, 
e.g. the inherited cardiomyopathies. 
The effect of GVs on phenotype (effect size) follows a gradient 
from none (indiscernible) to large (clinically consequential). The vast 
majority of GVs do not have significant biological effects. GVs that 
cause large phenotypic effects are usually responsible for single-gene 
disorders that exhibit Mendelian patterns of inheritance. Complex 
and polygenic disorders are primarily due to many common GVs, 
each exerting small, indiscernible effects, but collectively and through 
interactions with non-genetic factors, influencing the risk of the 
complex phenotype, e.g. coronary artery disease (CAD). GVs are 
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classified functionally as pathogenic, likely pathogenic, of uncertain 
significance, likely benign and benign (Table 2). 
Genetic cardiovascular conditions
CVD is caused by both genetic and environmental factors. In every 
condition, the interaction of genes with the environment is complex 
and profoundly affects phenotype. Genetic cardiovascular conditions 
may show incomplete or age-related penetrance, whereby individuals 
may not show signs of the condition until a certain age, or until 
environmental or lifestyle factors precipitate the manifestation of 
physical signs of the disease, e.g. hypertrophic cardiomyopathy (HCM) 
usually manifests in early adolescence during periods of rapid somatic 
growth. Genetic CVDs also demonstrate variable expressivity, whereby 
different family members with the same genetic mutation express 
the disease in different ways (i.e. varying severity). Expressivity is 
dependent upon environmental, lifestyle and background genetic 
modulators. Genetic cardiovascular conditions demonstrate clinical 
and genetic overlap, which may complicate the interpretation of genetic 
test results. Despite these caveats, knowledge of the genetic nature of a 
particular condition may be important – not only may it inform the 
need for familial screening and therefore early diagnosis and treatment 
to delay onset of disease, but it may also aid in risk stratification for 
sudden cardiac death (SCD) in affected individuals and potentially 
effect treatment and management decisions.[8]
Genetic cardiovascular conditions may be Mendelian (i.e. due to a 
single-gene defect) or non-Mendelian (i.e. due to complex, common 
GVs), or mitochondrial (Table 3). Most of these conditions display 
significant heterogeneity, i.e. locus, allelic and phenotypic. Locus 
heterogeneity refers to the phenomenon that numerous genes can 
result in the same clinical phenotype (e.g. >20 genes, mostly of the 
sarcomere, have been implicated in the aetiology of HCM). Allelic 
heterogeneity denotes various mutations, or alleles, within a gene, 
which can cause the same condition. Phenotypic heterogeneity 
refers to mutations in the same gene causing different phenotypes. 
For example, MYH7 gene mutations can cause HCM, dilated 
cardiomyopathy (DCM), left ventricular non-compaction (LVNC) 
or restrictive cardiomyopathy (RCM) and can also be associated 
with myopathy. Similarly, SCN5A gene mutations not only cause 
arrhythmia syndromes, such as long QT syndrome (LQTS), short 
QT syndrome (SQTS) and Brugada syndrome, but also DCM. This 
genetic diversity means that many mutations may be ‘private’, defined 
by their presence in only single families, with as many as 60 - 90% being 
described as private in the setting of cardiomyopathies.[9] Recurrent or 
‘founder’ mutations for certain conditions have been described, and 
may have important implications for certain conditions in South 
Africa (SA) (e.g. LQTS, HCM and familial hypercholesterolaemia 
(FH)). 
Single-gene disorders may be inherited as autosomal dominant 
(e.g. HCM, DCM, LVNC), autosomal recessive (e.g. LQTS, arrhyth-
mogenic right ventricular cardiomyopathy  (ARVC) with Naxos 
syndrome) or X-linked (e.g. Duchenne muscular dystrophy with cardiac 
involvement). Importantly, lack of family history does not imply that 
Table 1. Glossary of genetic terms used
Allele An allele is one of the possible forms of a gene. Most genes have two alleles, a dominant allele 
and a recessive allele. If an organism is heterozygous for that trait, or possesses one of each 
allele, then the dominant trait is expressed. A recessive allele is only expressed if an organism is 
homozygous for that trait, or possesses two recessive alleles. Alleles were first defined by  
Gregor Mendel in the law of segregation
Exome The DNA that is coded for in the exons of genes that code for proteins, i.e the ‘protein-coding’ 
regions of the genome 
Expressivity The degree to which a trait is expressed in an individual, i.e. the intensity of the phenotype
Founder A common mutation that occurs in higher frequency in a specific population due to a common 
ancestor 
Genome All the DNA contained in an organism or a cell, including nuclear and mitochondrial DNA 
Genotype The set of genes in our DNA that is responsible for a particular trait
Genome-wide association study Also known as whole-genome association study, is an observational study of a genome-wide set of 
genetic variants in different individuals to see if any variant is associated with a trait
Haplotype A haplotype (haploid genotype) is a group of alleles in an organism that are inherited together from 
a single parent
Heterogeneity Genetic heterogeneity occurs when mutations at two or more genetic loci produce the same or 
similar phenotypes (either biochemical or clinical) 
Homozygosity Genetic homozygosity describes a situation where an individual inherits the same alleles for  
a particular gene from both parents
Locus A locus (plural loci) in genetics is a fixed position on a chromosome, such as the position of 
a gene or a marker (genetic marker)
Mendelian genetics A Mendelian trait is one that is controlled by a single locus in an inheritance pattern. In such cases,  
a mutation in a single gene can cause a disease that is inherited according to Mendel’s laws. Examples 
include sickle cell anaemia and cystic fibrosis. Mendel’s studies yielded three ‘laws’ of inheritance:  
the law of dominance, the law of segregation and the law of independent assortment. Each of these 
can be understood through examining the process of meiosis
Mendelian randomisation A method of using measured variation in genes of known function to examine the causal effect of  
a modifiable exposure on disease in observational studies
Penetrance The probability of a gene or trait being expressed
Phenotype The physical expression, or characteristics, of that trait due to a specific genotype
Pleiotropy The ability of a single gene to influence multiple phenotypic traits
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the condition does not have a genetic basis, as it could represent a de 
novo mutation, incomplete penetrance or an uninformative family 
history.[10] Complex traits associated with polygenic states, such as 
serum low-density lipoprotein (LDL) cholesterol levels and CAD, are 
extremely common. Therefore, genetic heterogeneity from GVs across 
the frequency spectrum may be the rule. Consider plasma triglycerides: 
~50% of the inter-individual variability in plasma triglycerides is 
estimated to be based on GVs.[11] 
When to suspect an inherited 
cardiovascular disease
There are several key features of CVD that should raise suspicion 
of a strong genetic component to disease. These include extreme 
phenotypes: unexplained severe disease or early age of onset (childhood 
or early adulthood), presence of a family history, no identifiable 
environmental or other cause for the condition in an otherwise healthy 
individual (idiopathic), history of premature SCD, and presence of 
additional organ involvement or other syndromic features.[4] 
Discovering genes for cardiovascular 
disease
Traditionally, two major approaches for gene discovery in CVD have 
been used, i.e. linkage analysis and genetic association. The choice 
of approach has depended on the pattern of segregation of disease – 
whether consistent with Mendelian ratios or polygenic complexity.[12] 
For Mendelian forms of CVD, direct DNA sequencing and/or linkage 
analysis has successfully yielded causal genes and mutations. In 1985, 
Lehrman et al.[13] sequenced the LDL receptor gene in a patient with 
homozygous FH and uncovered a 5 kB deletion that eliminated 
several exons in the first demonstration of a mutation for Mendelian 
CVD. In 1989, linkage analysis was used to localise the chromosomal 
position of a causal gene for HCM.[14] Since then, there has been a 
plethora of discoveries for genes responsible for single-gene CVDs.
Lessons learnt from Mendelian forms 
of cardiovascular disease
Rare single-gene variants. Since Mendelian diseases are rare, there 
was initial scepticism regarding whether the genes and mechanisms 
that cause CVD would inform our understanding of common 
forms of the disease. Linkage studies have radically transformed our 
understanding of CVD. Selected examples of Mendelian diseases, the 
responsible genes, and the gleaned biological and clinical insights 
are detailed in Table 3. Of note is monogenic severe FH, where the 
6 responsible genes have led to fundamental new biological concepts 
and supported the development of new therapies.
Genotype-phenotype correlations. Since the early discovery 
of genes responsible for CVD, researchers have been looking for 
genotype-phenotype correlations to explain the impact of genetic 
background on physical signs. While there are clear examples where 
single-gene mutations lead to straightforward genotype-phenotype 
associations, often other more complex relationships also exist. The 
complexity arises from 3 distinct genetic phenomena: pleiotropy, 
penetrance and expressivity (Table 1). Pleiotropy, penetrance, 
expressivity and non-genetic factors conspire to ensure that even in 
single-gene disorders, genotype does not ‘equal’ a specific phenotype, 
with several important consequences: (i) gene discovery is more 
difficult, as genotype may not segregate perfectly with phenotype, 
reducing the power of linkage; (ii) there is intense interest in 
identifying modifiers – genetic or environmental – that modulate 
the relationship between genotype and phenotype; and (iii) in many 
Mendelian diseases, it has been difficult to develop genotype-specific 
prognostic or therapeutic recommendations.[12]
Tenuous path from gene discovery to understanding disease 
mecha nisms and developing targeted treatment. The ability to 
identify causative mutations is only the beginning of the pathophysio-
lo gical link. The underlying signalling pathways activated by the gene 
and protein need to be understood. Ultimately, putative therapeutic 
Table 2. Classification of genetic variants
Category Definition Utility for proband Utility for family
Pathogenic Loss-of-function and pathogenic variants shown to cause 
the disease through co-segregation and linkage analysis or 
functional studies in large families
Establishes diagnosis, 
may inform 
management
Can be used for predictive 
genetic testing
Likely pathogenic Evidence for the causal role based on statistical enrichment 
in small families and trios with the disease. Robust linkage is 
hindered by small size of families or sporadic nature of the 
disease. To reduce the possibility of random co-segregation 
in small families, findings require testing for replication in 
independent populations 
Possibly suggests 
diagnosis, may inform 
management or lead to 
additional diagnostic 
tests
Predictive genetic testing of 
unaffected relatives should 
be approached with great 
caution, may be combined 
with phenotypic evaluation 
and surveillance
Variant of unknown 
significance
Case-control studies will show an association between  
genetic variants and the phenotype. Replication in an 
independent study population is necessary. Disease- 
associated variants may be in linkage disequilibrium with  
the actual pathogenic variants, requiring additional studies  
to confirm actual pathogenicity
Unknown Should not be used for 
predictive genetic testing 
Testing of affected relatives 
for segregation may provide 
evidence of causality
Likely benign These variants may affect expression levels, structure and 
function of proteins, but have not been associated with 
disease 
None No option for predictive 
genetic testing, rely on 
longitudinal phenotypic 
evaluation
Benign Comprises the vast majority of genetic variants in the 
genome, which have absolutely no impact on protein 
expression, structure and function, and no impact on 
phenotype 
None No option for predictive 
genetic testing, rely on 
longitudinal phenotypic 
evaluation
Adapted from Marian et al.[6] and Cirino et al.[7] 
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targets must also be exploited. For example, in Marfan’s syndrome, the 
path from the discovery of FBN1 as the causal gene to a breakthrough 
in the molecular understanding of the disease took more than 2 decades. 
The importance of the role of transforming growth factor β (TGF-β) 
was not understood until recently. Microfibrils normally bind the large 
latent TGF-β complex, and failure of this to occur results in increased 
TGF-β activation and signalling. Investigators are currently exploring 
the hypothesis that blocking of TGF-β signalling will ameliorate the 
growth of aortic aneurysms in Marfan’s syndrome.[15]
Lessons learnt from complex 
polygenic and common forms of 
cardiovascular disease
GVs across the spectrum of allele frequency contribute to most 
complex and common diseases, as well as quantitative traits. There 
is a strong overlap between genome-wide association studies (GWAS) 
and genes identified through Mendelian families, e.g. 19 genes have 
been identified as monogenic causes of extremely low or high levels 
of LDL cholesterol, high-density lipoprotein (HDL) cholesterol and 
triglycerides; loci harbouring 16 of these genes were also mapped 
using GWAS. Monogenic and polygenic variants often coexist within 
the same condition. 
GWAS. The proportion of overall phenotypic variance explained 
by a GV may have little correlation with the ultimate therapeutic 
or biological value of the gene mapped by the GV. Phenotypic 
variance explained by a variant is a function of two key parameters, 
i.e. allele frequency and effect size. For Mendelian diseases, the 
causal variants typically confer large effects but explain a small 
proportion of trait variance due to their rare frequencies. GVs 
from GWAS are common but explain only a small proportion of 
trait variance due to modest effects. Nevertheless, variants that 
explain a small proportion of phenotypic variance may provide 
substantial biological or therapeutic insights. For example, GVs in 
introns of HMGCR confer a small effect on plasma LDL cholesterol; 
however, targeting of these genes with statins or ezetimibe has 
a much more dramatic effect on LDL cholesterol. To date, there 
have been no rare, large-effect Mendelian mutations described in 
HMGCR, presumably because such mutations are highly deleterious 
and not tolerated. Despite the success of GWAS, most mapped 
loci have been a challenge to move from genomic localisation 
to understanding the biological mechanism. The reasons for 
this observation are manifold: (i) in the context of discovery of 
Mendelian genes, inferring new biology from human genetics takes 
time and only about 13 years have elapsed since the initial GWAS 
publications; (ii) gene mapping and experimental follow-up require 
unique skill sets, expertise and collaboration; and (iii) genetic 
mapping by association gives us gene regions and not necessarily 
specific causal GVs or causal genes. 
GVs may distinguish causal from non-causal biomarkers. In 1961, 
Kannel et al.[16] established an association of plasma total cholesterol 
with future risk of CAD. Since then, hundreds of soluble biomarkers 
have similarly been associated with risk of CAD. The important 
question is how many of these biomarkers directly cause CAD and 
how many simply reflect other causal processes. Both causal and non-
causal biomarkers may predict risk for future disease, but only a causal 
biomarker may be appropriate as a therapeutic target. In Mendelian 
randomisation, DNA variants are used to address the question of 
whether an epidemiological association between a risk factor and 
disease reflects a causal influence of the former on the latter.[17] If, in 
an adequately powered sample, the predicted association between the 
GV and disease were not observed, it would argue against a causal 
role for the GV in the pathogenesis of the disease. 
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Next-generation sequencing 
approaches 
Next-generation sequencing platforms have markedly decreased the 
cost of DNA sequencing compared with Sanger sequencing. While 
whole-exome and whole-genome sequencing have been successfully 
used to identify new genes for several Mendelian forms of CVD, 
sequencing just the exome (rather than the entire genome) is 
justified in the search for genetic causes of rare inherited disorders 
because most alleles responsible for Mendelian disorders disrupt the 
protein-coding sequence. The yield of exome sequencing in solving 
Mendelian disorders is difficult to predict, as negative results have 
not been routinely reported.[18] It is often difficult to arrive at a single 
causal mutation after exome sequencing because: (i) the causal GV 
may not be protein coding (i.e. located in an intron); (ii) the causal 
GV may be protein coding but the relevant gene not successfully 
sequenced; (iii) if the causal mutation is not fully penetrant, it will be 
present in both phenotypically affected and unaffected individuals; 
(iv) segregation of a phenotype in a family may be due to non-genetic 
factors (e.g. in a multi-generation family, where multiple individuals 
are affected with MI, the pattern may be due to a new Mendelian 
gene or poor lifestyle habits shared by the family); and (v) in 
contrast to single nucleotide substitutions, methods for identifying 
small insertion-deletions and copy number changes from short-read 
sequence data are imprecise. For complex phenotypes (e.g. MI) that 
arise after decades of pathology, distinguishing functional v. neutral 
missense mutations is key. While advancements in sequencing 
techniques, and the development of various pathogenicity prediction 
tools and publicly available resources on variant frequency in large 
populations have been informative, clinical applicability remains a 
challenge.
Functional studies
Although technological advantages provide cumulative information 
of genetic causality, the prediction of pathogenicity and the 
interpretation of clinical consequences of a GV remain challenging. 
Functional assessment is the most powerful and well-validated 
strategy to elucidate the role of a candidate variant to the disease 
pathophysiology, as nothing is more convincing than in vivo data 
derived from animal models used to characterise the clinical 
phenotype and the mechanism by which the candidate GVs are 
shown to cause disease.[19] Knock-in and knock-out animal models 
have been employed for this purpose for decades, but animal models 
fail to fully recapitulate the human phenotype. 
Use of stem cells and programmed cells for understanding CVD. 
More recently, human adult somatic cells can be reprogrammed into 
a pluripotent state by activating differentiation transcription factors. 
Induced pluripotent stem (iPS) cells can differentiate into the specific 
cell types affected by disease. iPS cells have provided an unprecedented 
opportunity to investigate the consequences of human GV on cellular 
phenotypes that may contribute to disease. iPS cells have contributed 
enormously to understanding the biology of LQTS, HCM, DCM 
and Noonan syndrome. The ability to refine functional effects of 
GVs has been advanced through the use of zinc-finger nucleases and 
transcription activator-like effector nuclease (TALEN) and clustered 
regularly interspaced short palindromic repeats (CRISPR)-associated 
protein 9 (Cas9) technology that specifically introduces or removes 
GVs in stem cells to reveal the contribution of individual GVs to 
cellular phenotypes.
Use of zebrafish to study human CVD. Zebrafish possess a variety 
of features that are advantageous for use as an experimental model 
organism for the study of CVD. Due to their small size (2 - 4 cm), 
zebrafish are easy to handle and one female can produce ~200 eggs per 
week. Zebrafish embryos develop externally and very rapidly to freely 
swimming and fed larvae within 5 days. The zebrafish is an excellent 
system for microscopic applications, as embryos are transparent and 
numerous transgenic fluorescent reporter lines are available. Because 
of their suitability for imaging applications, zebrafish are also highly 
interesting for high-throughput small compound screens. They are 
ideal for the study of heart development and disease: (i) zebrafish 
heart development proceeds fast and results in a differentiated two-
chambered heart within 48 hours postfertilisation; (ii) zebrafish 
embryos, in contrast to mammalian or avian embryos, are able to 
cover their oxygen demand by diffusion during the first days of 
development and are not dependent on blood circulation. This 
enables the investigation of gene knock-outs or knock-downs, even 
if they lead to severe defects of the cardiovascular system; and 
(iii) humans and zebrafish share a 70% sequence similarity, and 84% 
of human disease-causing genes can also be found in the zebrafish 
genome. The different morphology of the zebrafish heart limits 
the translation of findings into the mammalian system; without a 
coronary artery system during embryogenesis, zebrafish show a 
vasculature on the heart surface, which restricts the study of CAD. 
Functional verification of candidate genes using CRISPR-Cas9 has 
supported the role of several genes in the pathophysiology of CVD. 
Zebrafish hearts maintain their ability to regenerate throughout their 
lifetime, providing novel insights to understanding human cardiac 
regeneration.[20]
The future of genetic applications in 
cardiovascular disease
The widespread use and availability of genetic approaches for the 
diagnosis of CVD have allowed the study of direct and indirect genetic 
predisposition, prevention of CVD, genetic testing, population 
screening and precision cardiology, including pharmacogenetics 
and pharmacogenomics. In the future, the ability to use specific 
therapies based on specific genotypes will be widespread (as is 
already the case in oncology), as will gene therapy for specific single-
gene disorders. Barriers to implementing these advances in general 
cardiology include the inability of physicians to interpret genetic test 
results and provide appropriate counselling, poor understanding of 
risk probabilities and growing concern with ethical issues related 
to emerging genetics and genomics. A major challenge, already 
evident, is how LMICs will have access to novel and costly research 
and commercial genetic advances, including genetic screening on a 
broad scale. A major inequity that needs addressing in the future is 
the dearth of data on the genetic underpinnings of CVD in SSA. Our 
group has recently shown that a gene panel with a yield of >60% in a 
European population has a yield of 18% in South Africans with HCM, 
highlighting the need to identify genetic causes of CVD in Africans.[21] 
Similarly, GVs identified in non-SSA populations need to be treated 
with caution until population screening in local populations has 
been performed and verified as pathogenic, as it has previously been 
demonstrated that rare GVs in European populations could represent 
common GVs in African populations. 
Genetic testing recommendations and 
genetic counselling 
Different types of genetic testing include pre-implantation testing, 
diagnostic testing at any age, carrier testing, pre-symptomatic testing, 
postmortem testing, pharmacogenomic testing, risk-prediction 
testing and direct-to-consumer testing. Importantly, all genetic 
testing should be based on careful case definition and accurate 
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phenotyping. In patients suspected of having familial disease, the 
first step is to construct a family pedigree, which often informs the 
pattern of inheritance. If the pedigree suggests a Mendelian pattern 
of inheritance (e.g. autosomal dominant, autosomal recessive or 
X-linked recessive), cascade clinical screening is recommended. 
After informed consent and a comprehensive counselling process by 
a qualified professional, DNA should be obtained from the proband 
(clinically affected index patient) for genetic testing. If a causative 
GV is identified, it can be useful in: (i) clarifying the diagnosis in a 
person who has or is suspected of having CVD; (ii) identifying the 
cause of CVD in a family; (iii) providing options for family planning, 
including pre-implantation genetic diagnosis to avoid having affected 
offspring; and (iv) predicting which family members are at increased 
risk of developing CVD by offering predictive testing to unaffected 
family members. Those family members who have the mutation 
will require close medical follow-up, as they are at increased risk of 
developing CVD. Individuals who test negative for the mutation are 
unlikely to develop the disease and, therefore, do not usually require 
clinical follow-up and can be reassured. Successful predictive testing 
in families relies on a high degree of certainty that the GV identified 
is pathogenic and considered causal of the CVD in a specific family. 
Interpretation of genetic testing warrants caution. For example, a 
negative result in a proband means that the laboratory has been 
unable to identify a disease-causing mutation in the genes evaluated. 
It is nevertheless possible that the cause of the CVD is genetic. 
Similarly, the discovery of new GVs should be viewed with caution 
until these have been subjected to functional testing in large family 
pedigrees or in independent populations. The physician must always 
be prepared for the wide range of emotional reactions, including 
anger, guilt, grief, sadness, fear and anxiety, which accompany a new 
genetic diagnosis or misdiagnosis.
Conclusions
Technological advances are unravelling the genetic underpinnings of 
CVD and have ushered in a new era of genetically informed diagnosis 
of both rare and common forms of CVD. It is important for clinicians 
to understand the capabilities and limitations of genetic and genomic 
testing in different clinical settings and to translate these into clinical 
practice. 
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